Celldex Price Target Raised to $88 Following Successful Barzolvolimab Trials

Key Facts

1Leerink Partners raised the price target for Celldex Therapeutics to $88.00 from $70.00.

2Phase III clinical trials for barzolvolimab in chronic spontaneous urticaria met all primary endpoints.

3The company plans to submit a Biologics License Application (BLA) in 2027 for FDA approval.

Reflecting growing optimism in biotech innovation, Leerink Partners has significantly raised its price target for Celldex Therapeutics (CLDX) to $88.00 from $70.00. This upgrade follows successful Phase III clinical trials for barzolvolimab, a treatment for chronic spontaneous urticaria (CSU), which met all primary endpoints in the EMBARQ-CSU1 and EMBARQ-CSU2 studies. According to reports, the company is now positioned to submit a Biologics License Application (BLA) to the FDA in 2027.

Despite the clinical success, market data showed CLDX shares declined by 6.03% to $31.49 during daily trading, likely pressured by the discontinuation of a separate Phase 2 trial for barzolvolimab in a different condition. However, the analyst's bullish outlook remains supported by the robust Phase III data involving 1,939 patients, which demonstrated sustained efficacy over 24 weeks. The company currently maintains a market capitalization of approximately $2.1 billion.

CLDX closed at $33.51 as of September 22, 2026, within a daily range of $30.39 to $38.39. Investors should monitor future regulatory milestones as the company prepares its 2027 BLA submission. While no immediate domestic catalysts are scheduled in the upcoming calendar, broader market sentiment remains sensitive to global inflation data and central bank decisions from the UK and Japan recorded earlier this week.